Concentra Group Holdings Parent, Inc. (CON)
NYSE:CON
Top Page
Concentra Group Holdings Parent, Inc.
(NYSE:CON)
Select Model
Select Model
Rating:59Neutral
Price Target:
$22.50
▲(5.49% Upside)
Action:ReiteratedDate:04/08/26
The score is held back primarily by balance-sheet leverage volatility and weak technical momentum, partially offset by solid cash generation, reasonable valuation (mid-teens P/E with a dividend), and positive recent corporate updates including strong results and an improved 2026 outlook.
Positive Factors
Market position / Scale
Large national footprint and leading share create durable competitive advantages: lower cost-per-claim, broader employer contracts, and higher bargaining power with payors. Scale supports consistent visit volumes and makes market entry harder for smaller competitors over the medium term.
Negative Factors
Leverage volatility and balance-sheet risk
Volatile leverage reduces financial resilience: swings in debt load amplify refinancing and interest-rate sensitivity, constrain strategic flexibility, and increase downside risk if cash flows soften, making capital structure a medium-term vulnerability.
Read all positive and negative factors
Positive Factors
Negative Factors
Market position / Scale
Large national footprint and leading share create durable competitive advantages: lower cost-per-claim, broader employer contracts, and higher bargaining power with payors. Scale supports consistent visit volumes and makes market entry harder for smaller competitors over the medium term.
Read all positive factors
Concentra Group Holdings Parent, Inc. (CON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.82B
Dividend Yield1.27%
Average Volume (3M)760.18K
Price to Earnings (P/E)14.4
Beta (1Y)0.51
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8,758
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)0.28
Shares Outstanding128,634,750
10 Day Avg. Volume653,827
30 Day Avg. Volume760,182
Financial Highlights & Ratios
PEG Ratio2.08
Price to Book (P/B)6.34
Price to Sales (P/S)1.15
P/FCF Ratio12.65
Enterprise Value/Market Cap1.72
Enterprise Value/Revenue2.24
Enterprise Value/Gross Profit7.90
Enterprise Value/Ebitda11.84
Forecast
1Y Price Target
$29.00Price Target Upside35.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.46
Revenue Forecast (FY)$2.31B
Concentra Group Holdings Parent, Inc. Business Overview & Revenue Model
Company Description
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers' compensation injury care, urgent care, clinical testing, preventativ...
How the Company Makes Money
Concentra primarily makes money by charging employers and other payors for occupational health services delivered through its medical centers and on-site programs. Key revenue streams include: (1) treatment and clinical care related to workplace i...
Concentra Group Holdings Parent, Inc. Key Performance Indicators (KPIs)
Any
Revenue By Segment
Data provided by:
The Fly
The FlyConcentra Group Holdings Parent, Inc. Earnings Call Summary
Earnings Call Date:Mar 09, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: double-digit headline revenue growth, meaningful volume and rate gains, adjusted EBITDA expansion, robust free cash flow and validation of clinical outcomes. Management also highlighted successful integration of acquisitions and a sizable de novo/M&A pipeline with a 2026 guidance band that targets continued growth and ~20% adjusted EBITDA margin. Offsetting factors include elevated investing activity and one-time integration/separation costs, a higher G&A run-rate from separation, increased financing costs and a net leverage ratio (3.4x) above the company target of ~3.0x. Organic growth excluding acquisitions was more moderate, and certain state reimbursement dynamics (e.g., New York) limit expansion opportunities until rates improve. On balance, positive operational execution and financial performance materially outweigh the near-term and transitional headwinds.Positive Updates
Revenue Growth — Q4 and Full Year
Total company revenue of $539.1M in Q4 2025, up 15.9% YoY from $465.0M; excluding Nova and Pivot Q4 revenue was $493.8M (+6.2% YoY). Full year 2025 revenue of $2.2B, up 13.9% YoY from $1.9B; excluding acquisitions full year revenue was $2.0B (+6.4% YoY; +6.8% on a per-day basis).
Negative Updates
Adjusted EPS Decline Full Year
Full-year adjusted EPS decreased to $1.37 in 2025 from $1.48 in 2024 despite higher adjusted EBITDA and adjusted net income, indicating share count or other dilution/earnings-per-share dynamics that pressured EPS.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Growth — Q4 and Full Year
Total company revenue of $539.1M in Q4 2025, up 15.9% YoY from $465.0M; excluding Nova and Pivot Q4 revenue was $493.8M (+6.2% YoY). Full year 2025 revenue of $2.2B, up 13.9% YoY from $1.9B; excluding acquisitions full year revenue was $2.0B (+6.4% YoY; +6.8% on a per-day basis).
Read all positive updates
Company Guidance
The company’s full‑year 2026 guidance calls for revenue of $2.25–$2.35 billion, adjusted EBITDA of $450–$470 million, CapEx of $70–$80 million, free cash flow of $200–$225 million, and a year‑end net leverage target of ~3.0x (down from 3.4x at 12/31/25); key assumptions include ~3% rate growth in the Occupational Health Centers segment, low‑single‑digit visit growth excluding Nova, inclusion of the January three‑center acquisition and six de‑novo sites with executed leases (and an overall de‑novo target of 7–9 sites in 2026), adjusted EBITDA margin roughly flat at ~20%, modest incremental separation/TSA costs early in 2026 with TSA costs ramping toward zero by mid‑year, and an expected ~ $15 million decline in CapEx as one‑time Nova integration spend rolls off.Concentra Group Holdings Parent, Inc. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
46
Neutral
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 2.16B | 1.90B | 1.84B | 1.72B |
| Gross Profit | 613.09M | 527.98M | 512.43M | 408.19M |
| EBITDA | 408.88M | 368.26M | 360.15M | 330.20M |
| Net Income | 172.80M | 166.54M | 179.95M | 166.73M |
Balance Sheet | ||||
| Total Assets | 3.04B | 2.52B | 2.49B | 2.30B |
| Cash, Cash Equivalents and Short-Term Investments | 79.90M | 183.25M | 31.37M | 37.66M |
| Total Debt | 2.10B | 1.95B | 905.00M | 1.04B |
| Total Liabilities | 2.62B | 2.22B | 1.31B | 1.30B |
| Stockholders Equity | 393.28M | 275.67M | 1.16B | 973.32M |
Cash Flow | ||||
| Free Cash Flow | 197.06M | 210.35M | 164.98M | 228.35M |
| Operating Cash Flow | 279.40M | 274.68M | 234.32M | 274.34M |
| Investing Cash Flow | -414.86M | -71.27M | -75.31M | -57.75M |
| Financing Cash Flow | 32.10M | -51.53M | -165.29M | -209.86M |
Concentra Group Holdings Parent, Inc. Technical Analysis
Negative
21.33
Price Trends
22.60
Negative
21.30
Positive
21.06
Positive
Market Momentum
-0.44
Positive
42.30
Neutral
29.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CON, the sentiment is Negative. The current price of 21.33 is below the 20-day moving average (MA) of 21.84, below the 50-day MA of 22.60, and above the 200-day MA of 21.06, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 42.30 is Neutral, neither overbought nor oversold. The STOCH value of 29.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CON.
Concentra Group Holdings Parent, Inc. Risk Analysis
Concentra Group Holdings Parent, Inc. disclosed 63 risk factors in its most recent earnings report. Concentra Group Holdings Parent, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Concentra Group Holdings Parent, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.94B | 12.21 | 43.60% | 1.32% | ― | ― | |
62 Neutral | $22.64B | 23.81 | 10.28% | 1.14% | 8.28% | 97.24% | |
61 Neutral | $4.37B | 77.60 | 1.52% | ― | 4.73% | ― | |
59 Neutral | $2.82B | 14.42 | 46.60% | 1.27% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $434.50M | -22.93 | -24.45% | ― | 67.01% | -39.19% | |
43 Neutral | $82.51M | -4.96 | -182.65% | ― | ― | ― |
* Healthcare Sector Average
CON
Concentra Group Holdings Parent, Inc.
21.91
1.01
4.82%
LH
Labcorp Holdings
274.72
46.69
20.47%
NVST
Envista Holdings
26.66
10.22
62.17%
SPAI
Safe Pro Group, Inc.
3.95
1.74
78.73%
FLOC
Flowco Holdings Inc Class A
21.25
1.33
6.69%
BBNX
Beta Bionics, Inc.
9.79
-2.02
-17.10%
Concentra Group Holdings Parent, Inc. Corporate Events
Business Operations and StrategyDividendsFinancial Disclosures
Concentra Posts Strong Q4 Results and Declares Dividend
Positive
Feb 26, 2026
Concentra Group Holdings Parent, Inc. reported strong fourth-quarter and full-year 2025 results on February 26, 2026, with Q4 revenue up 15.9% to $539.1 million and net income up 58.7% to $36.2 million, driven by higher patient volume, increased r...
Business Operations and StrategyStock BuybackFinancial Disclosures
Concentra Posts Strong Q4 Results and Raises 2026 Outlook
Positive
Jan 28, 2026
On January 28, 2026, Concentra announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing that it exceeded its prior full-year guidance and extended its lead in the U.S. occupational hea...
Business Operations and StrategyFinancial Disclosures
Concentra Showcases Growth and Scale at Healthcare Conference
Positive
Jan 12, 2026
In an investor presentation prepared for the J.P. Morgan Healthcare Conference in January 2026, Concentra highlighted its position as the dominant U.S. occupational health provider, treating about one in four workplace injuries and operating more ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.